Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Combination IOP Lowering Therapy · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Combination IOP Lowering Therapy | DRUG | - |
Adult patients of any race and either sex with open angle glaucoma or ocular hypertension.
Combination IOP Lowering Therapy is an investigational small molecule being studied for the treatment of open-angle glaucoma and ocular hypertension. It is designed to lower intraocular pressure (IOP) in patients with these conditions. The therapy is currently in Phase 2 clinical development.
Combination IOP Lowering Therapy is being developed by Alcon Inc., a company traded on the New York Stock Exchange under the ticker symbol ALC. Alcon is conducting clinical research on this therapy for the treatment of open-angle glaucoma and ocular hypertension.
Combination IOP Lowering Therapy is in Phase 2 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to evaluate its safety and efficacy in patients with open-angle glaucoma or ocular hypertension.
Combination IOP Lowering Therapy has one completed Phase 2 clinical trial registered as NCT00051194. This was a 6-week, randomized, double-blind study conducted in the United States to evaluate the safety and efficacy of the therapy in patients with open-angle glaucoma or ocular hypertension.
No alternative names for Combination IOP Lowering Therapy have been disclosed. The therapy is identified by its descriptive name and is being developed by Alcon Inc. for the treatment of open-angle glaucoma and ocular hypertension.